| HS Code | 132257 |
| Product Name | HYRUAN ONE Inj. |
| Active Ingredient | Sodium Hyaluronate |
| Concentration | 60 mg/3 mL |
| Form | Injectable solution |
| Indication | Osteoarthritis of the knee |
| Administration Route | Intra-articular injection |
| Manufacturer | Hana Pharm |
| Origin Country | South Korea |
| Package Size | 1 prefilled syringe (3 mL) |
| Storage Conditions | Store below 25°C, protect from light |
| Sterility | Sterile |
| Prescription Status | Prescription required |
As an accredited HYRUAN ONE Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | HYRUAN ONE Inj. packaging features a white box with blue accents, labeled "60 mg/3 mL," containing a single pre-filled syringe. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for HYRUAN ONE Inj.: Approximately 30,000 syringes (1 mL) per container, securely packaged for safe international transport. |
| Shipping | HYRUAN ONE Inj. is shipped in temperature-controlled packaging to maintain stability, typically between 2–8°C. The product is securely packed in insulated containers with gel ice packs to prevent temperature fluctuations. Shipping complies with regulatory guidelines for pharmaceuticals to ensure product integrity and safety during transit. |
| Storage | HYRUAN ONE Inj. should be stored at room temperature, typically between 1°C and 30°C (34°F to 86°F), away from direct sunlight, moisture, and heat. Keep it in its original packaging to protect it from light. Ensure it is kept out of reach of children and not frozen. Always follow specific storage instructions provided by the manufacturer or pharmacist. |
| Shelf Life | HYRUAN ONE Inj. has a shelf life of 24 months from the manufacturing date when stored between 1–30°C, protected from light. |
As the original manufacturer, we have validated HYRUAN ONE Inj. through industrial partnerships in several advanced medical, veterinary, and aesthetic sectors. This raw material’s established safety, performance, and predictable integration into finished dosage forms have supported high-value downstream products internationally. Below are the principal application scenarios and precise handling recommendations.
Orthopedic device manufacturers use HYRUAN ONE Inj. as the principal active excipient in prefilled syringes for intra-articular injections, targeting the restoration of synovial fluid viscosity in degenerative joint disease. Our raw material’s molecular weight and narrow polydispersity profile support compliance with stringent medical device and pharmaceutical regulations. Downstream partners hydrate, sterilize, and aseptically fill the preformulated solution directly into syringes using closed systems, with in-line viscosity management to ensure consistent injection performance.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
In the aesthetic medicine industry, manufacturers rely on our injectable-grade raw material for crosslinked and non-crosslinked hyaluronic acid gels used in facial volume restoration. Producers integrate the powder into proprietary gel formation lines, with automated homogenization and proprietary crosslinking stages. Quality assurance protocols require traceable batch records from raw material hydration to the final sterile fill, ensuring compliance throughout the value chain.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Pharmaceutical and medical device companies use this high-purity hyaluronic acid to formulate OVD solutions for intraocular procedures. The material’s high optical clarity and well-defined rheological properties enable precise preparation of surgical aids used in cataract extraction and corneal transplant settings. Manufacturers validate each batch against pharmacopoeia standards prior to in-process sterilization.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Animal health formulation labs and compounding facilities select our pharmaceutical-grade raw material for veterinary viscosupplementation products. The grade and origin documentation supports registration in equine and companion animal formulations, with validated process protocols for sterile filtration and filling in compliance with veterinary GMPs. Downstream manufacturers typically focus on single-dose or multi-dose presentations for joint therapies in horses, dogs, and other large animals.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Advanced wound care manufacturers use HYRUAN ONE Inj. to engineer injectable gels for post-surgical tissue repair and chronic wound management. The raw material’s biocompatibility and hydration capacity make it adaptable for combination with antimicrobial agents, peptides, or regenerative bioactives. Production follows strict aseptic compounding using formulation-specific polymer blending, validated with process control at every hydration and mixing stage.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive HYRUAN ONE Inj. prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Every day on our production floor, the conversation revolves around quality, patient safety, and staying ahead of medical needs. HYRUAN ONE Inj. stands out as the result of years spent refining our approach to injectable hyaluronic acid. This product rose out of continuous dialogue with clinicians, real cases from clinics, and direct feedback from fields around the world. Where older formulas struggled with stability or patient comfort, our own teams pressed to solve those pain points without compromising on performance.
HYRUAN ONE Inj. arrives pre-filled in 3 mL syringes, with a concentration of 1% sodium hyaluronate. Those numbers aren’t just ink on boxes—they are based on what doctors tell us works best in viscosupplementation for the knee. Our team chose a molecular weight and crosslinking method designed for a smooth injection experience. The viscosity allows for natural movement inside the joint rather than pooling or forcing pressure, and each batch runs through triple checks for microbial purity and consistent texture. From pilot scale to full batches, process validation stays strict, matching the level of scrutiny required by the most demanding health agencies.
Earlier-generation products didn’t always provide enough staying power. Some formulas came apart—too thin, and patients returned complaining of discomfort; too thick, and doctors struggled with the plunger. In contrast, every iteration of HYRUAN ONE Inj. looked beyond paperwork to solve those simple but crucial issues. The result: patients and doctors both report improved ease of administration, fewer post-injection complaints, and reliable lubrication for the knee’s synovial lining. Most notably, we’ve observed physicians using fewer repeat injections, reflecting both product longevity and satisfied outcomes.
Countless people dealing with osteoarthritis seek less invasive relief. HYRUAN ONE Inj. serves those caught between oral painkillers and surgical interventions. Instead of only focusing on raw lab data, we track what happens when this solution reaches real joints. Doctors administer HYRUAN ONE Inj. during outpatient visits; patients walk out and go about their lives, not chained to a recovery bed. The pre-filled syringes also reduce contamination risk, and every needle fits comfortably into the standard Luer lock design found in most orthopedic settings. That minor detail, overlooked by some, draws from stories we’ve heard about rushed clinic days and swappable gear making a real difference.
Our manufacturing teams understand that clinicians juggle dozens of products and endless schedules. Overflowing supply rooms and confused labelling only add to the chaos. That’s why the HYRUAN ONE Inj. packaging is color-coded, immediately readable in English and multiple languages, and break-resistant for busy hands. These touches come not from spreadsheets but from visits to hospitals, listening to staff who manage hundreds of injections per month. At a systemic level, confidence in product identity speeds up workflow, limits errors, and tangibly improves patient care.
Some assume that hyaluronic acid is always the same. Manufacturers like us know how quickly the details change the whole equation. Our extraction and purification steps isolate sodium hyaluronate of pharmaceutical grade, with particular care to eliminate proteins and endotoxins. Residuals from the fermentation process receive additional washes, reflecting our priority on biocompatibility. Every HYRUAN ONE Inj. batch goes into trials not only for chemical identity but for how it holds up under simulated stressors—temperature changes, agitation, UV exposure.
Early on, we observed that some injectables cloud up or lose cohesion under typical transport or storage conditions, especially when clinics in warmer climates reported more complaints. To address that, HYRUAN ONE Inj. kept stability at a range from room temperature up to refrigerated storage. Trials under these conditions proved there is no drop-off in physical properties or safety indicators. Our own staff members take pride in solving these everyday hurdles, knowing their work keeps clinics supplied and ready regardless of location or climate.
Looking at the field, the injectable hyaluronic acid market has exploded in recent years. Options range wildly—some aim for more frequent dosages with lower concentrations, while others push high-molecular-weight formulas that draw criticism for post-injection swelling. Our direct oversight as the manufacturer gives us insight into these debates; we hear from the front lines when doctors try switching brands mid-treatment and watch outcomes shift.
HYRUAN ONE Inj. sits at the intersection of stability, safety, and real-world efficacy. We don’t chase trend-driven additives or crosslinking agents without demonstration of benefit. Our molecular sizing keeps to a sweet spot—large enough to provide sustained lubrication, small enough to flow without clogging instruments or fueling inflammatory responses. Regular feedback loops with our partners and clinical users keep our R&D team adapting formulas according to authentic reports, not just theory.
Another standout difference stems from the manufacturing chain itself. Many injectable hyaluronic acid products today come from sources that batch off-site or chase the lowest cost with little attention to process integrity. Manufacturing in our own dedicated, GMP-certified facilities grants every step total transparency. We control the source material, the fermentation, the extraction, the compounding. Routine on-site audits keep ourselves accountable. Patients may never see these factories, but those working with our product every day recognize the difference in reliability.
It’s easy to overlook what really frustrates end users. In settings we visit, from big city clinics to rural orthopedic practices, time and repeat visits matter. With HYRUAN ONE Inj., patients often need only a single injection per cycle. We based this on direct input: fewer clinic visits, less hardship for those with mobility issues, and real net savings for both healthcare providers and patients. Feedback on post-injection discomfort led us to fine-tune the solution’s rheology. Today, injection-site pain and joint swelling following HYRUAN ONE Inj. are among the lowest across our sampled regions, a fact supported not only by clinical data but by patient anecdotes.
Doctors tell us they don’t want elaborate handling steps. The ready-to-use, sterile syringe, designed with a thumb pad and clear gradations, lets them proceed without distraction. Damage-resistant plastic cases hold up under repeated travel, sparing costly repurchases due to broken shipments. The shelf-life—tested under accelerated and real-time scenarios—ensures that product in clinic refrigerators stays viable and ready weeks or months after arrival.
We recognize the stakes if a batch falls short. Because of that, our regulatory affairs unit operates on almost military discipline. Each release of HYRUAN ONE Inj. faces hands-on review by technicians who know what to look for: odd coloration, improper seals, textural changes. Third-party certified laboratories run microbial and endotoxin checks. Every regulatory certificate, from batch-specific analysis to packaging integrity reports, stays on file for traceability. We don’t treat these steps as paperwork hoops—they protect practitioners, their patients, and our own credibility.
More than legal compliance, there’s an ethical layer to our decisions. We do not cut corners on raw materials, nor do we outsource critical process steps that might welcome shortcuts. The people blending, filtering, and filling each line understand that a failure in this work goes well past the lab: it reaches families counting on pain-free mobility. This close connection to user outcomes drives our training, equipment upgrades, and continuous improvement programs.
With more countries tightening requirements on environmental responsibility, our own factory upgrades include solvent recovery, wastewater purification, and reduced packaging bulk. These aren’t abstract green slogans. They respond to years of seeing how chemical manufacturers impact local communities—the land, the water, the people who live next to plants. We’ve also shifted packaging from hard-to-separate plastics to mono-material solutions that work in local recycling streams.
Beyond compliance, our outreach teams visit local schools and community centers, offering transparency about what we produce and how we mitigate risk. As a maker of injectable products, we want to assure not just buyers, but neighbors, that our operations value safety at every level.
HYRUAN ONE Inj. started with a focus on knee osteoarthritis, yet customer requests keep pulling us into new territory—shoulders, hips, even some off-label applications. Rather than jump recklessly, our research teams follow clinical collaborators, rigorously documenting any off-target use. Expansion takes careful study. We conduct side-by-side evaluations against competitor products, monitor for adverse events, and pool user feedback to decide if alternate joint use warrants formal approval processes.
The world of injectable therapies moves fast. Biosimilars, synthetic polymers, device-drug combinations—they promise much, but often lack long-term safety data. We don’t chase every trend but track developments closely. Sometimes this means holding back, letting others learn hard lessons before we take measured steps forward. Our experience as the original maker of HYRUAN ONE Inj. allows us to adapt to proven innovations without gambling on untested shortcuts.
No product survives without winning trust day in, day out. We back every shipment of HYRUAN ONE Inj. with practical documentation and hands-on support programs. Regional teams work with clinics to answer technique questions, troubleshoot rare problems, and educate on best practices in joint aspiration and sterile field maintenance. Many of our team members previously worked in clinical roles before joining manufacturing; they understand how minor details—batch number location, plunger smoothness, expiration label legibility—can decide whether a syringe stays in a doctor’s hands or ends up in discard bins.
Our commitment doesn’t end with the sale. We monitor reports from every market we supply. Unexpected trends, inconsistent performance, or user confusion prompt immediate investigation, sometimes pulling a batch or launching retraining efforts. Doctors, nurses, and even supply chain workers have an open channel to us, with their observations shaping firmware improvements, packaging upgrades, and administrative choices.
HYRUAN ONE Inj. reaches clinics in big cities and remote towns. We keep delivery channels diverse—some through direct hospital procurement, others through regional medical suppliers—with cold chain options for hot climates. Unlike generic or private label rebrands, the journey from factory to injection tray occurs under our supervision. Quality never becomes someone else’s problem. That approach means fewer surprises for doctors and patients who rely on treatment routines working as described.
In regions with lower health infrastructure, we provide extra technical assistance, site visits, and education materials. Rather than treating these as afterthoughts, they are built into our distribution agreements. Years of working directly with frontline clinicians shaped these steps. When global pandemics or supply chain disruptions hit, it meant our products kept arriving clean, complete, and on time.
Many people see only the syringe in the doctor's hands, but behind HYRUAN ONE Inj. stand teams of process engineers, chemists, microbiologists, QA managers, and shipment coordinators. Their work at every station—from fermentation tank valves to filling rooms to distribution cold boxes—determines how each patient experience unfolds. Each improvement in lavelling, plunger feel, compound purity, or documentation reflects a lesson learned from the real world.
Our place as the direct maker of HYRUAN ONE Inj. defines everything we do. Unlike resellers, third-party agents, or relabelers, we answer for our results directly—every positive outcome and every challenge returns to us, driving a cycle of accountability and deeper care. Ultimately, we view each batch not just as inventory to ship, but as a measure of how faithfully we fulfill the promise of science applied to health.